Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 20 |
| Active Pipeline (Recruiting Now) | 14 (5) |
| Completed vs Stopped Early | 5 / 1 (5.0%) |
| Median Closed Actual Enrollment | 21 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 8 (2 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Northwestern Memorial and Lurie Cancer Center | Chicago, IL | 8 |
| Children's National Medical Center | Washington D.C, DC | 4 |
| Cincinnati Children's Hospital Medical Center | Cincinnati, OH | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07441876 | Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia | Phase II/III | RECRUITING |
| NCT07126262 | A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months | Phase II | RECRUITING |
| NCT06382155 | A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature | Phase II | RECRUITING |
| NCT03989947 | An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia | Phase II | ACTIVE NOT RECRUITING |
| NCT06668805 | A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase II | ACTIVE NOT RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the BioMarin Pharmaceutical Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.